Related Experiment Video
Updated: Jul 16, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Drug-eluting stent: a review and update
1Division of Cardiovascular Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Vascular Health and Risk Management
|February 24, 2007
Summary
Drug-eluting stents (DES) significantly reduce restenosis after percutaneous coronary intervention compared to bare metal stents. Ongoing research explores their use in complex cases, with DES becoming a cost-effective option for all patients.
Area of Science:
- Interventional Cardiology
- Cardiovascular Disease Research
Background:
- Obstructive coronary artery disease treatment has advanced with stenting.
- Neointimal hyperplasia causing in-stent restenosis remains a challenge in percutaneous coronary intervention (PCI).
Purpose of the Study:
- To review the progress and development of drug-eluting stents (DES).
- To compare and update clinical trial results for DES.
- To discuss the expanding applications and economic viability of DES.
Main Methods:
- Review of large randomized clinical trials and non-controlled clinical trials.
- Analysis of evidence from everyday practice.
- Summarization of ongoing studies evaluating complex lesion applications.
Main Results:
- Drug-eluting stents (DES) show a significant reduction in restenosis and target vessel revascularization compared to bare metal stents.
- Clinical trial data and real-world evidence support the efficacy of DES.
- Expanded applications of DES in complex lesions are under evaluation.
Conclusions:
- DES represent a major breakthrough in interventional cardiology, improving PCI outcomes.
- Further studies are evaluating DES for complex coronary lesions.
- DES are becoming increasingly cost-effective and may soon be standard for all PCI procedures.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...